Literature DB >> 26463319

Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights.

Jason Yongsheng Chan1, Yukti Choudhury2, Min-Han Tan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26463319     DOI： 10.1016/j.eururo.2015.09.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  2 in total

1.  A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.

Authors:  Maria I Carlo; Ana M Molina; Yulia Lakhman; Sujata Patil; Kaitlin Woo; John DeLuca; Chung-Han Lee; James J Hsieh; Darren R Feldman; Robert J Motzer; Martin H Voss
Journal:  Oncologist       Date:  2016-06-10

2.  A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

Authors:  Edward Wolin; Alain Mita; Amit Mahipal; Tim Meyer; Johanna Bendell; John Nemunaitis; Pam N Munster; Luis Paz-Ares; Ellen H Filvaroff; Shaoyi Li; Kristen Hege; Hans de Haan; Monica Mita
Journal:  PLoS One       Date:  2019-09-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.